SAN DIEGO, June 2, 2021 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company
focused on the development of new solid tumor cancer therapies,
announced today that Chief Executive Officer Saiid Zarrabian will present a corporate
overview at the three-day LD Micro Virtual Invitational Conference
being held on June 8 – 10, 2021.
Mr. Zarrabian will deliver his corporate presentation on
June 9 at 2:30
pm ET, Track 1.
Register to watch the presentation here.
Investors interested in scheduling a meeting with management
should contact assistant@ldmicro.com.
About Kintara
Located in San
Diego, California, Kintara (Nasdaq: KTRA) is dedicated to
the development of novel cancer therapies for patients with rare
unmet medical needs. Kintara is currently developing two Phase
3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and
REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule
chemotherapeutic with a novel mechanism of action that has
demonstrated clinical activity against a range of cancers,
including central nervous system, ovarian and other solid tumors
(e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical
trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these
prior NCI-sponsored clinical studies, Kintara is
currently conducting clinical trials to support the development and
commercialization of VAL-083 in GBM.
REM-001 is a proprietary, late-stage photodynamic therapy
platform that holds promise as a localized cutaneous, or visceral,
tumor treatment as well as in other potential indications.
REM-001 therapy has been previously studied in four Phase 2/3
clinical trials in patients with CMBC who had previously received
chemotherapy and/or failed radiation therapy. With clinical
efficacy of 80% complete responses of CMBC evaluable lesions and an
existing robust safety database of approximately 1,100 patients
across multiple indications, Kintara is advancing
the REM-001 CMBC program to late-stage pivotal
testing.
For more information, please visit www.kintara.com or
follow us on Twitter
at @Kintara_Thera, Facebook and Linkedin.
Safe Harbor Statement
Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995, including statements
regarding the status of the Company's clinical trials and the GBM
AGILE study. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the impact
of the COVID-19 pandemic on the Company's operations and clinical
trials; the Company's ability to develop, market and sell products
based on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including the Company's Annual Report on Form 10-K
for the year ended June 30, 2020, the
Company's Quarterly Reports on Form 10-Q, and the Company's Current
Reports on Form 8-K.
CONTACTS
Investors
CORE IR
516-222-2560
ir@coreir.com
Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-ld-micro-virtual-invitational-conference-on-june-9-2021-301303789.html
SOURCE Kintara Therapeutics